Abstract:Abstract Background Little is known about the relationship between the metabolite profile of plasma from pre-operative prostate cancer (PCa) patients and the risk of PCa progression. In this study we investigated the association between pre-operative plasma metabolites and risk of biochemical-, local- and metastatic-recurrence, with the aim of improving patient stratification. Methods We conducted a case-control study within a cohort of PCa patients recruited between 1996 and 2015. The age-matched primary cases ( n = 33) were stratified in low risk, high risk without progression and high risk with progression as defined by the National Comprehensive Cancer Network. These samples were compared to metastatic ( n = 9) and healthy controls ( n = 10). The pre-operative plasma from primary cases and the plasma from metastatic patients and controls were assessed with untargeted metabolomics by LC-MS. The association between risk of progression and metabolite abundance was calculated using multivariate Cox proportional-hazard regression and the relationship between metabolites and outcome was calculated using median cut-off normalized values of metabolite abundance by Log-Rank test using the Kaplan Meier method. Results Medium-chain acylcarnitines (C6-C12) were positively associated with the risk of PSA progression ( p = 0.036, median cut-off) while long-chain acylcarnitines (C14-C16) were inversely associated with local ( p = 0.034) and bone progression ( p = 0.0033). In primary cases, medium-chain acylcarnitines were positively associated with suberic acid, which also correlated with the risk of PSA progression ( p = 0.032, Log-Rank test). In the metastatic samples, this effect was consistent for hexanoylcarnitine, L.octanoylcarnitine and decanoylcarnitine. Medium-chain acylcarnitines and suberic acid displayed the same inverse association with tryptophan, while indoleacetic acid, a breakdown product of tryptophan metabolism was strongly associated with PSA ( p = 0.0081, Log-Rank test) and lymph node progression ( p = 0.025, Log-Rank test). These data were consistent with the increased expression of indoleamine 2,3 dioxygenase (IDO1) in metastatic versus primary samples ( p = 0.014). Finally, functional experiments revealed a synergistic effect of long chain fatty acids in combination with dihydrotestosterone administration on the transcription of androgen responsive genes. Conclusions This study strengthens the emerging link between fatty acid metabolism and PCa progression and suggests that measuring levels of medium- and long-chain acylcarnitines in pre-operative patient plasma may provide a basis for improving patient stratification.

The Expression Of C-Fabp And Ppar Gamma And Their Prognostic Significance In Prostate Cancer

Identification of novel biomarkers differentially expressed between African-American and Caucasian-American prostate cancer patients

Free Fatty Acids Promote the Development of Prostate Cancer by Upregulating Peroxisome Proliferator-Activated Receptor Gamma

FABP5 Can Substitute for Androgen Receptor in Malignant Progression of Prostate Cancer Cells.

Inactivated FABP5 Suppresses Malignant Progression of Prostate Cancer Cells by Inhibiting the Activation of Nuclear Fatty Acid Receptor PPARγ

The Clinicopathological Significance and Prognostic Value of Programmed Death-Ligand 1 in Prostate Cancer: a Meta-Analysis of 3133 Patients

FASN Protein Overexpression Indicates Poor Biochemical Recurrence-Free Survival in Prostate Cancer

Expression and Clinical Significance of FPARγ and Β-Catenin in Breast Cancer

Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC)

P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth

Ppar Gamma And Wnt/Beta-Catenin Pathway In Human Breast Cancer: Expression Pattern, Molecular Interaction And Clinical/Prognostic Correlations

Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification

Characterizing adipocytokine-related signatures for prognosis prediction in prostate cancer

Prognostic Significance And Therapeutic Implications Of Peroxisome Proliferator-Activated Receptor Gamma Overexpression In Human Pancreatic Carcinoma

Comprehensive analysis of fatty acid metabolism-related gene signatures for predicting prognosis in patients with prostate cancer

[P53 Expression and Its Clinical Significance in Prostatic Carcinoma].

Meta-analysis and Clinical Evaluation of the Relationship Between FAPalpha Expression and Malignant Degree of Solid Tumors

Prostate-specific membrane antigen modulates the progression of prostate cancer by regulating the synthesis of arginine and proline and the expression of androgen receptors and Fos proto-oncogenes

Experimental Treatment Efficacy of Dmrfabp5 on Prostate Cancer Singly or in Combination with Drugs in Use

Emerging Biomarker Associated with Prognosis of Prostate Cancer Identified Via Co-Expression Analysis

Classical and Alternative Nuclear Factor-κB Pathways: A Comparison among Normal Prostate, Benign Prostate Hyperplasia and Prostate Cancer